NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if this combo can shrink tumors or slow the disease. About 29 adults will t…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New hope for lung cancer patients whose current meds stop working?
Disease control OngoingThis study tests a new drug called AK112 combined with standard chemotherapy in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has a mutation in the EGFR gene and has stopped responding to initial targeted therapy. About 322 participants wi…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
AI-Designed vaccine takes on tough lung cancers
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a personalized vaccine called Microlyvaq™ in 90 people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their tumor's unique features. It is given alongside standard chemothe…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for lung cancer patients who stopped responding to standard therapy
Disease control OngoingThis study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) live longer without their cancer growing. Participants must have already tried and failed an EGFR-targ…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:20 UTC